|Related Categories||Aminoglycosides, Antibacterial, Antibiotics, Antibiotics A to Z, Antibiotics T-Z,|
Tobramycin is an aminoglycoside.
Mode of Action: Binds to 70S ribosomal subunit; inhibits translocation; elicits miscoding.
Spectrum of Activity: Gram negative bacteria. Not effective against Enterococci.
Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial membranes by binding to 16 S r-RNA. It inhibits translocation and elicits miscoding.
Tobramycin is an aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is not effective against Enterococci. It is used to inhibit bacterial protein synthesis. It is used to treat pseudomonas aeruginosa lung infections and is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, sepsis, respiratory infections, osteomyelitis, and other soft-tissue infections. It is a potential therapy for sinus infections1.
Increasing antibiotic resistance and the lack of new drug development have hindered the success of antibiotics in recent years. Staph aureus is susceptible to a number of antibiotics with various mec...
Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. Daneman N, Sarwar S, Fowler RA, et al. Lancet Infect. Dis. 13(4), 328-41, (2013)
Articulating spacers for the treatment of infected total knee arthroplasty: effect of antibiotic combinations and concentrations. Nettrour JF, Polikandriotis JA, Bernasek TL, et al. Orthopedics 36(1), e19-24, (2013)
Evaluating effectiveness of antibiotic polymethylmethacrylate beads in achieving wound sterilization and graft preservation in patients with early and late vascular graft infections. Poi MJ, Pisimisis G, Barshes NR, et al. Surgery 153(5), 673-82, (2013)
Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients. Govoni M, Poli G, Acerbi D, et al. Pulm. Pharmacol. Ther. 26(2), 249-55, (2013)
Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Schuster A, Haliburn C, Döring G, et al. Thorax 68(4), 344-50, (2013)
Cost-effectiveness of perioperative selective decontamination of the digestive tract versus placebo in elective gastrointestinal surgery. Dijksman LM, Roos D, Gerhards MF, et al. Dig. Surg. 29(5), 384-90, (2012)
Contribution of the production of quormones to some phenotypic characteristics of Pseudomonas aeruginosa clinical strains. Nagant C, Seil M, Nachtergael A, et al. J. Med. Microbiol. 62(Pt 7), 951-8, (2013)
Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Alhariri M and Omri A Antimicrob. Agents Chemother. 57(1), 569-78, (2013)
Effects of decontamination of the digestive tract and oropharynx in intensive care unit patients on 1-year survival. Oostdijk EA, de Smet AM, and Bonten MJ Am. J. Respir. Crit. Care Med. 188(1), 117-20, (2013)
Correlations between aminoglycoside consumption and aminoglycoside resistance in Gram-negative bacteria at a tertiary-care hospital in South Korea from 2001 to 2011. Ku NS, Choi JY, Yong D, et al. Int. J. Antimicrob. Agents 41(4), 394-5, (2013)
In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection. Kowalski RP, Kowalski TA, Shanks RM, et al. Cornea 32(6), 830-4, (2013)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?